This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

AMRI Promotes Steven R. Hagen, Ph.D., To Senior Vice President Of Pharmaceutical Development And Manufacturing

ALBANY, N.Y., Oct. 22, 2012 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that Steven R. Hagen, Ph.D., has been promoted to senior vice president of pharmaceutical development and manufacturing. He will continue to report to AMRI Chairman, President and CEO Thomas E. D'Ambra, Ph.D. Dr. Hagen is responsible for approximately two-thirds of AMRI's contract operations, including Chemical Development, Analytical and Pharmaceutical Quality Services, Small Scale cGMP Manufacturing of active ingredients and dosage forms, and Large Scale Commercial Manufacturing. These operations encompass facilities located in Albany, Rensselaer and Syracuse, New York; Burlington, Massachusetts; Holywell, Wales (UK) and Hyderabad and Aurangabad, India.

(Logo: )

"We are pleased to announce this promotion of Dr. Hagen," said Dr. D'Ambra. "Under Dr. Hagen's leadership, AMRI has experienced growth within key sectors of AMRI's business. Additionally, Dr. Hagen has overseen the continued expansion and adherence to world class compliance programs and milestones, as well as the consistent attainment of operating performance metrics in AMRI's manufacturing area."

Dr. D'Ambra continued, "Steve has surrounded himself with a first class team and together they have continued to drive improvement and performance in our pharmaceutical services development and manufacturing operations and created industry leading quality compliance and project management functions. As a result, AMRI has been able to distinguish itself in Steve's areas of responsibility in a highly competitive marketplace and continues to cement relationships with multiple customers throughout the world as a partner of choice for their development and supply of a large number of exciting new medicines. I am confident Dr. Hagen will continue to deliver the leadership that is needed in order to enhance our SMARTSOURCING™ approach while continuing to improve profitability in these business sectors. We are pleased to recognize Steve's continuing contributions to AMRI with this promotion to Senior Vice President."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,678.23 -40.31 -0.23%
S&P 500 2,056.15 -4.90 -0.24%
NASDAQ 4,863.3620 -13.1570 -0.27%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs